Recombinant human erythropoietin stimulates angiogenesis and wound healing in the genetically diabetic mouse

The effects of recombinant human erythropoietin (rHuEPO) in diabetes-related healing defects were investigated by using an incisional skin-wound model produced on the back of female diabetic C57BL/KsJ-m(+/+)Lept(db) mice (db(+)/db(+)) and their normoglycemic littermates (db(+/+)m). Animals were treated with rHuEPO (400 units/kg in 100 mul s.c.) or its vehicle alone (100 mul). Mice were killed on different days (3, 6, and 12 days after skin injury) for measurement of vascular endothelial growth factor (VEGF) mRNA expression and protein synthesis, for monitoring angiogenesis by CD31 expression, and for evaluating histological changes. Furthermore, we evaluated wound-breaking strength at day 12. At day 6, rHuEPO injection in diabetic mice resulted in an increase in VEGF mRNA expression (vehicle=0.33+/-0.1 relative amount of mRNA; rHuEPO=0.9+/-0.09 relative amount of mRNA; P<0.05) and protein wound content (vehicle=23 +/- 5 pg/wound; rHuEPO=92 +/- 12 pg/wound; P<0.05) and caused a marked increase in CD31 gene expression (vehicle 0.18+/-0.05 relative amount of mRNA; rHuEPO 0.98+/-0.21 relative amount of mRNA; P<0.05) and protein synthesis. Furthermore, rHuEPO injection improved the impaired wound healing and, at day 12, increased the wound-breaking strength in diabetic mice (vehicle=12 +/- 2 g/mm; rHuEPO 21 +/- 5 g/mm; P<0.05). Erythropoietin may have a potential application in diabetes-related wound disorders.